Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma

Mayo Clinic Proceedings

Volumn 85, Issue 3, 2010, Pages 232-238

  Madan, Sumit ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Buadi, Francis ^a   Hayman, Suzanne R ^a   Zeldenrust, Steven R ^a   Rajkumar, S Vincent ^a   Gertz, Morie A ^a   Kumar, Shaji K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; INCIDENTAL FINDING; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SUBCUTANEOUS FAT; TREATMENT RESPONSE;

EID: 77649224583     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0547     Document Type: Article

References (21)

1. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569.
3. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998;82(8):1501-1505.
4. Desikan KR, Dhodapkar MV, Hough A, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma. 1997;27(3-4):315-319.
5. Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 1992;6(2):347-358.
6. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328.
7. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
8. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.
9. Dispenzieri A, Merlini G, Comenzo RL. Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol Blood Marrow Transplant. 2008;14(suppl 1):6-11.
10. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA. Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid. 2005;12(2):120-126.
11. Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801-3808.
12. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753(1):11-22.
13. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141-157.
14. Leung N, Dispenzieri A, Lacy MQ, et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol. 2007;2(3):440-444.
15. Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol. 2009;88(1):59-66.
16. Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant. 2006;38(1):7-15.
17. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125(6):681-700.
18. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91(10):3662-3670.
19. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101(4):766-769.
20. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276-4282.
21. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-2938.